Matthew Richard Moore - 29 Aug 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
SVP and Chief Business Officer
Signature
/s/ John W. Smither, Attorney-in-Fact for Matthew Richard Moore
Issuer symbol
ARQT
Transactions as of
29 Aug 2023
Net transactions value
$0
Form type
4
Filing time
12 Sep 2023, 07:39:50 UTC
Previous filing
06 Mar 2023
Next filing
17 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (Right to Buy) Award $0 +12,500 $0.000000 12,500 29 Aug 2023 Common Stock 12,500 $28.72 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares vest on each monthly anniversary of the milestone vesting commencement date, beginning on September 29, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.